
    
      This study will determine the safety and tolerability, pharmacokinetics, and pharmacodynamics
      of single ascending doses of XmAb27564 in normal healthy volunteers. XmAb27564 is an
      engineered IL-2 mutein being developed for autoimmune diseases.
    
  